Communiqués ASKA Pharmaceutical Holdings Co.,Ltd.

Actions

4886

JP3119660003

Temps Différé Japan Exchange Autres places de cotation 02:35:21 12/06/2024			Varia. 5j.	Varia. 1 janv.
2 340 ^JPY	-0,59%		+1,87%	+31,05%

2023	ASKA Pharmaceutical Holdings Co. annonce ses résultats pour l'exercice clos le 31 mars 2023	CI
2020	ASKA Pharmaceutical Co., Ltd. annonce le versement d'un dividende pour l'exercice clos le 31 mars 2020, payable le 26 juin 2020 ; fournit des prévisions de dividendes pour le deuxième trimestre et l'exercice clos le 31 mars 2021 ; annonce les résultats des bénéfices consolidés pour l'exercice clos le 31 mars 2020 ; fournit des prévisions de bénéfices consolidés pour l'exercice clos le 31 mars 2021.	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

ASKA Pharmaceutical : May 31 2024 Licensing Agreement for Relugolix Combination Tablet for Endometriosis in the Gynecologic Disease Area	31/05	PU
ASKA Pharmaceutical : April 25 2024 Personnel Changes of ASKA Pharmaceutical Holdings' Subsidiaries	25/04	PU
ASKA Pharmaceutical : March 26 2024 ASKA Pharmaceutical Receives Approval for Partial Change of Manufacturing and Marketing Approval for RIFXIMA® TABLETS for Pediatric Indication	26/03	PU
ASKA Pharmaceutical : March 21 2024 Newsweek International Features ASKA Pharmaceutical	21/03	PU
ASKA Pharmaceutical : November 13 2023 ASKA Pharmaceutical Featured in a Special Feature in TIME Magazine	14/11	PU
ASKA Pharmaceutical : September 21 2023 ASKA Pharmaceutical Holdings Participates at 2nd Femtech Tokyo	22/09/23	PU
ASKA Pharmaceutical : September 14 2023 Newsweek International Features ASKA Pharmaceutical	14/09/23	PU
ASKA Pharmaceutical : July 20 2023 ASKA Pharmaceutical Initiates Domestic Phase I II Clinical Trial of Relugolix Combination Tablet (AKP-022)	20/07/23	PU
ASKA Pharmaceutical : June 27 2023 Personnel Changes of Corporate Officers and Board Members of ASKA Pharmaceutical Holdings Subsidiaries	27/06/23	PU
ASKA Pharmaceutical : June 22 2023 ASKA Pharmaceutical Files an Application for Partial Change of Manufacturing and Marketing Approval for RIFXIMA	22/06/23	PU
ASKA Pharmaceutical : June 12 2023 Matters Subject to Measures for Electronic Provision of the Notice of the 2nd Annual General Meeting of Shareholders	11/06/23	PU
ASKA Pharmaceutical : June 12 2023 NOTICE OF CONVOCATION OF THE 2nd ANNUAL GENERAL MEETING OF SHAREHOLDERS	11/06/23	PU
ASKA Pharmaceutical : June 9 2023 ASKA Pharmaceutical Terminates Joint Research Agreement regarding the Drug Discovery Targeting Specific Ion Channels with RaQualia Pharma	09/06/23	PU
ASKA Pharmaceutical : April 24 2023 ASKA Pharmaceutical Enters into a Comprehensive Business Alliance Agreement on Femtech	24/04/23	PU
ASKA Pharmaceutical : April 21 2023 ASKA Pharmaceutical Holdings Installs CO₂-Free Electricity and Solar Power Generation Facilities	21/04/23	PU
ASKA Pharmaceutical : April 7 2023 ASKA licensee Hyundai files New Drug Application in Korea for OC Drospirenone	07/04/23	PU
ASKA Pharmaceutical : April 7 2023 ASKA Pharmaceutical Terminates Option Agreement with KinoPharma regarding Cervical Dysplasia Treatment	07/04/23	PU
ASKA Pharmaceutical : March 27 2023 Personnel Change of ASKA Pharmaceutical	27/03/23	PU
ASKA Pharmaceutical : March 6 2023 Organizational and Personnel Changes of ASKA Pharmaceutical	06/03/23	PU
ASKA Pharmaceutical : February 7 2023 EME and ASKA Announce Collaboration Agreement on Creating Novel PharmaLogical® VHH to address an unmet medical need in Obstetrics and Gynecology	07/02/23	PU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués ASKA Pharmaceutical Holdings Co.,Ltd.

Actions

4886

JP3119660003

Communiqués

Filtres